中国乙型肝炎疫苗免疫策略及接种进展

唐林; 许侠; 周泽玫; 王晓琪; 李继贞; 尹遵栋; 王富珍

doi:10.12449/JCH250203

中国乙型肝炎疫苗免疫策略及接种进展

DOI: 10.12449/JCH250203

唐林^{1, 2},
许侠^{1, 2},
周泽玫^{1, 2},
王晓琪^{1, 2},
李继贞^{1, 2},
尹遵栋^{1, 2},
王富珍^{1, 2, , ,}

1.
中国疾病预防控制中心免疫规划中心，北京 100050
2.
中国疾病预防控制中心传染病溯源预警与智能决策全国重点实验室，北京 102206

基金项目:

国家自然科学基金 (11571272)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：唐林、许侠、周泽玫负责设计论文框架，起草论文；王晓琪、李继贞负责文献收集、绘制图表；唐林、许侠负责论文修改；尹遵栋、王富珍负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
王富珍， wangfz@chinacdc.cn （ORCID： 0000-0002-6784-7711）

计量
- 文章访问数: 2059
- HTML全文浏览量: 62
- PDF下载量: 47
- 被引次数: 0
出版历程
- 收稿日期: 2025-01-03
- 录用日期: 2025-01-10
- 出版日期: 2025-02-25

Strategies and advances in hepatitis B vaccination in China

Lin TANG^{1, 2},
Xia XU^{1, 2},
Zemei ZHOU^{1, 2},
Xiaoqi WANG^{1, 2},
Jizhen LI^{1, 2},
Zundong YIN^{1, 2},
Fuzhen WANG^{1, 2
, ,
,}

1.
National Immunization Program，Chinese Center for Disease Control and Prevention，Beijing 100050，China
2.
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases，Chinese Center for Disease Control and Prevention，Beijing 102206，China

Research funding:

National Natural Science Foundation of China (11571272)

More Information

Corresponding author: WANG Fuzhen， wangfz@chinacdc.cn （ORCID： 0000-0002-6784-7711）

摘要

摘要: 乙型肝炎是全球重要的公共卫生问题。我国通过实施以乙型肝炎疫苗为核心的综合防控策略，在乙型肝炎防控方面取得了显著成效，但仍存在诸多问题和挑战。本文回顾了我国乙型肝炎免疫策略的发展历程，分析了不同人群的疫苗接种目标与进展，以及存在的问题及挑战，为进一步优化免疫策略和提升防控水平提供参考。
- 乙型肝炎疫苗 /
- 免疫 /
- 接种 /
- 疫苗，联合
Abstract: Hepatitis B is a major global public health issue. Through the implementation of comprehensive prevention and control strategies centered on hepatitis B vaccination， China has achieved remarkable progress in hepatitis B prevention and control， while there are still many issues and challenges. This article reviews the development of hepatitis B vaccination strategies in China， analyzes the goal and advances in vaccination in different populations， and problems and challenges， in order to provide a reference for further optimizing vaccination strategies and improving the levels of prevention and control.
- Hepatitis B Vaccines /
- Immunity /
- Vaccination /
- Vaccines， Combined

HTML全文

注： HepB₁，第1剂HepB。

图 1 中国乙型肝炎疫苗免疫策略历程

Figure 1. The evolution of hepatitis B vaccination strategies in China

下载: 全尺寸图片幻灯片

注：数据来源于2006年和2014年全国乙型肝炎血清流行病学调查数据，以及常规免疫报告数据。

图 2 1992—2022年中国新生儿HepB接种率

Figure 2. Hepatitis B vaccination coverage among newborns in China， 1992—2022

下载: 全尺寸图片幻灯片

参考文献(46)

[1]	World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022- 2030[EB/OL].( 2022-07-18)[ 2024-11-25]. https://www.who.int/publications/i/item/9789240053779. https://www.who.int/publications/i/item/9789240053779
[2]	CUI FQ, BLACH S, MANZENGO MINGIEDI C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C[J]. Lancet Gastroenterol Hepatol, 2023, 8( 4): 332- 342. DOI: 10.1016/S2468-1253(22)00386-7.
[3]	GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 796- 829. DOI: 10.1016/S2468-1253(22)00124-8.
[4]	ZHENG H, WANG Y, WANG FZ, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: Evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51: 101193. DOI: 10.1016/j.lanwpc.2024.101193.
[5]	WANG FZ, ZHENG H, SUN XJ, et al. Achievements and prospects for hepatitis B prevention and control in China[J]. Chin J Vaccines Immun, 2019, 25( 5): 487- 492. 王富珍, 郑徽, 孙校金, 等. 中国控制乙型病毒性肝炎的成就与展望[J]. 中国疫苗和免疫, 2019, 25( 5): 487- 492.
[6]	COLLABORATORS PO. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3( 6): 383- 403. DOI: 10.1016/S2468-1253(18)30056-6.
[7]	LIU J, WANG XY, WANG Q, et al. Hepatitis B virus infection among 90 million pregnant women in 2 853 Chinese counties, 2015-2020: A national observational study[J]. Lancet Reg Health West Pac, 2021, 16: 100267. DOI: 10.1016/j.lanwpc.2021.100267.
[8]	ZHAO K, ZHANG YH. History of the Development of Biological Products in China(1910—1990)[M]. Beijing: Beijing Institute of Biological Products, 2003. 赵铠, 章以浩. 中国生物制品发展史略: 1910—1990[M]. 北京: 北京生物制品研究所, 2003.
[9]	ZHAO H, ZHOU XY, ZHOU YH. Hepatitis B vaccine development and implementation[J]. Hum Vaccin Immunother, 2020, 16( 7): 1533- 1544. DOI: 10.1080/21645515.2020.1732166.
[10]	LIANG XF, BI SL, YANG WZ, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J]. J Infect Dis, 2009, 200( 1): 39- 47. DOI: 10.1086/599332.
[11]	WANG AL, SONG L. Safeguarding the starting point of life to protect maternal and child health: A review and prospect of the prevention of mother-to-child transmission of HIV, syphilis and hepatitis B in China in the past 20 years[J]. Chin J AIDS STD, 2021, 27( 7): 677- 679. DOI: 10.13419/j.cnki.aids.2021.07.01. 王爱玲, 宋莉. 守护生命起点保障母婴健康: 中国预防艾滋病梅毒和乙肝母婴传播工作20年回顾与展望[J]. 中国艾滋病性病, 2021, 27( 7): 677- 679. DOI: 10.13419/j.cnki.aids.2021.07.01.
[12]	WANG AL, QIAO YP, WANG LH, et al. Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China[J]. Bull World Health Organ, 2015, 93( 1): 52- 56. DOI: 10.2471/BLT.14.139626.
[13]	National Health Commission. Immunization schedules and instructions for vaccines of the national immunization program(2021 version)[EB/OL].( 2021-03-12)[ 2024-11-25]. http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml. http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml 国家卫生健康委. 国家免疫规划疫苗儿童免疫程序及说明(2021年版)[EB/OL].( 2021-03-12)[ 2024-11-25]. http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml. http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml
[14]	World Health Organization. Hepatitis B vaccines: WHO position paper-July 2017[J]. Wkly Epidemiol Rec, 2017, 92( 27): 369- 392. DOI: 10.1016/j.vaccine.2017.07.046.
[15]	World Health Organization. Global health sector strategy on viral hepatitis 2016- 2021[EB/OL].( 2016-06-01)[ 2024-11-25]. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
[16]	Ministry of Health. National plan for hepatitis B prevention and treatment, 2006-2010[J]. Chin Pract J Rural Dr, 2006, 13( 8): 1- 4. DOI: 10.3969/j.issn.1672-7185.2006.08.001. 中华人民共和国卫生部. 2006年～2010年全国乙型病毒性肝炎防治规划[J]. 中国实用乡村医生杂志, 2006, 13( 8): 1- 4. DOI: 10.3969/j.issn.1672-7185.2006.08.001.
[17]	National Health and Family Planning Commisson, National Development and Reform Commisson, Ministry of Education, et al. Action plan for the prevention and treatment of viral hepatitis in China( 2017-2020)[EB/OL].( 2017-11-10)[ 2024-11-25]. http://www.nhc.gov.cn/jkj/s3581/201711/aea94a8c1d9d4110a13e2b4d8418c173.shtml. http://www.nhc.gov.cn/jkj/s3581/201711/aea94a8c1d9d4110a13e2b4d8418c173.shtml 国家卫生计生委, 国家发展改革委, 教育部, 等. 中国病毒性肝炎防治规划( 2017- 2020 年)[EB/OL].( 2017-11-10)[ 2024-11-25]. http://www.nhc.gov.cn/jkj/s3581/201711/aea94a8c1d9d4110a13e2b4d8418c173.shtml. http://www.nhc.gov.cn/jkj/s3581/201711/aea94a8c1d9d4110a13e2b4d8418c173.shtml
[18]	National Health Commission. Action Plan for Eliminating Mother-to-child Transmission of AlDS, Syphilis and Hepatitis B( 2022-2025)[EB/OL].( 2022-12-30)[ 2024-11-25]. http://www.nhc.gov.cn/fys/s3581/202212/afe6bc9626be45a0b25bee93f01fef10.shtml. http://www.nhc.gov.cn/fys/s3581/202212/afe6bc9626be45a0b25bee93f01fef10.shtml 国家卫生健康委员会. 消除艾滋病、梅毒和乙肝母婴传播行动计划( 2022- 2025 年)[EB/OL].( 2022-12-30)[ 2024-11-25]. http://www.nhc.gov.cn/fys/s3581/202212/afe6bc9626be45a0b25bee93f01fef10.shtml. http://www.nhc.gov.cn/fys/s3581/202212/afe6bc9626be45a0b25bee93f01fef10.shtml
[19]	World Health Organization. Immunization coverage[EB/OL].( 2024-07-15)[ 2024-12-18]. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage
[20]	Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association, Chinese Society of Perinatal Medicine, Chinese Medical Association. 2020 clinical guidelines on prevention of mother-to-child transmission of hepatitis B virus[J]. J Clin Hepatol, 2020, 36( 7): 1474- 1481. DOI: 10.3760/cma.j.cn112141-20200213-00101. 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 乙型肝炎病毒母婴传播预防临床指南(2020)[J]. 临床肝胆病杂志, 2020, 36( 7): 1474- 1481. DOI: 10.3760/cma.j.cn112141-20200213-00101.
[21]	YIN XR, WANG W, CHEN H, et al. Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China[J]. Nat Med, 2024, 30( 2): 455- 462. DOI: 10.1038/s41591-023-02782-x.
[22]	YE JK, CAO L, YU WZ, et al. Reported routine immunization coverage with National Immunization Program vaccines in China, 2020-2021[J]. Chin J Vaccines Immun, 2022, 28( 5): 576- 580. DOI: 10.19914/j.CJVI.2022110. 叶家楷, 曹雷, 余文周, 等. 中国2020—2021年国家免疫规划疫苗常规免疫报告接种率[J]. 中国疫苗和免疫, 2022, 28( 5): 576- 580. DOI: 10.19914/j.CJVI.2022110.
[23]	LIU J, LIANG WN, JING WZ, et al. Countdown to 2030: Eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97( 3): 230- 238. DOI: 10.2471/BLT.18.219469.
[24]	MIAO N, WANG FZ, ZHENG H, et al. Hepatitis B vaccine coverage and factors influencing coverage among children 1-14 years of age in China in 2020[J]. Chin J Vaccines Immun, 2022, 28( 6): 679- 683. DOI: 10.19914/j.CJVI.2022125. 缪宁, 王富珍, 郑徽, 等. 2020年中国1-14岁儿童乙型肝炎疫苗接种率和影响因素[J]. 中国疫苗和免疫, 2022, 28( 6): 679- 683. DOI: 10.19914/j.CJVI.2022125.
[25]	HUANG LF, HUANG AD, ZHANG X, et al. Immunization status and factors influencing hepatitis B vaccination of preterm infants in three provinces of China, 2019 to 2021[J]. BMC Infect Dis, 2024, 24( 1): 951. DOI: 10.1186/s12879-024-09846-4.
[26]	ZHENG H, WANG FZ, CHEN YS, et al. The hepatitis B prevalence and the vaccination statutes of the 1-14 years-old children in eastern, central and western areas of China[J]. Chin J Vaccines Immun, 2012, 18( 1): 19- 25. DOI: 10.19914/j.cjvi.2012.01.005. 郑徽, 王富珍, 陈园生, 等. 中国东中西部地区1～14岁儿童乙型病毒性肝炎流行现状及乙型肝炎疫苗接种情况[J]. 中国疫苗和免疫, 2012, 18( 1): 19- 25. DOI: 10.19914/j.cjvi.2012.01.005.
[27]	HU YH, DUNZHU DJ, LI Q/X), et al. Epidemiological survey of hepatitis B and analysis of hepatitis B vaccine coverage rate among children aged 1-14 years in Lhasa in 2006, 2014 and 2020[J]. Chin J Prev Med, 2023, 57( 3): 406- 410. DOI: 10.3760/cma.j.cn112150-20221105-01072. 胡永红, 顿珠多吉, 李茜, 等. 2006和2014及2020年拉萨市1～14岁儿童乙肝流行病学调查及乙肝疫苗接种率分析[J]. 中华预防医学杂志, 2023, 57( 3): 406- 410. DOI: 10.3760/cma.j.cn112150-20221105-01072.
[28]	World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[EB/OL].( 2024-03-29)[ 2024-12-18]. https://www.who.int/publications/i/item/9789240090903. https://www.who.int/publications/i/item/9789240090903
[29]	SANDUL AL, RAPPOSELLI K, NYENDAK M, et al. Updated recommendation for universal hepatitis B vaccination in adults aged 19-59 years- United States, 2024[J]. MMWR Morb Mortal Wkly Rep, 2024, 73( 48): 1106. DOI: 10.15585/mmwr.mm7348a3.
[30]	WU ZK, BAO HD, YAO J, et al. Suitable hepatitis B vaccine for adult immunization in China: A systematic review and meta-analysis[J]. Hum Vaccin Immunother, 2019, 15( 1): 220- 227. DOI: 10.1080/21645515.2018.1509172.
[31]	Working Committee of Promoting the Elimination of Viral Hepatitis of Chinese Preventive Medicine Association, Society of Prevention and Control of Infectious Diseases of Chinese Preventive Medicine Association. Expert recommendations on hepatitis B vaccination in adults[J]. J Clin Hepatol, 2024, 40( 8): 1551- 1556. DOI: 10.12449/JCH240808. 中华预防医学会促进消除病毒性肝炎工作委员会, 中华预防医学会感染性疾病防控分会. 成人乙型肝炎疫苗接种专家建议[J]. 临床肝胆病杂志, 2024, 40( 8): 1551- 1556. DOI: 10.12449/JCH240808.
[32]	ZHENG H, WANG FZ, ZHANG GM, et al. The epidemiological characteristics of HBV susceptibility in 1-29 years old young people in China in 2006 and 2014: Based on the national sero-survey data analysis[J]. Chin J Prev Med, 2017, 51( 7): 581- 586. DOI: 10.3760/ema.j.issn.0253-9624.2017.07.002. 郑徽, 王富珍, 张国民, 等. 2006和2014年中国1-29岁乙型肝炎病毒易感人群的流行病学特征分析[J]. 中华预防医学杂志, 2017, 51( 7): 581- 586. DOI: 10.3760/ema.j.issn.0253-9624.2017.07.002.
[33]	MA TL, PAN LL, GAO Z, et al. Influencing factors of coverage rate of hepatitis B vaccine among adults in Hebei Province[J]. Chin Prev Med, 2019, 20( 4): 303- 307. DOI: 10.16506/j.1009-6639.2019.04.014. 马田莉, 潘璐璐, 高招, 等. 河北省成年人乙肝疫苗接种率影响因素研究[J]. 中国预防医学杂志, 2019, 20( 4): 303- 307. DOI: 10.16506/j.1009-6639.2019.04.014.
[34]	XU Y, WU QQ, XU SY, et al. Analysis on hepatitis B vaccination and its influencing factors among adults in Zhejiang Province[J]. Chin J Health Educ, 2020, 36( 3): 259- 261, 284. DOI: 10.16168/j.cnki.issn.1002-9982.2020.03.015. 许燕, 吴青青, 徐水洋, 等. 浙江省部分地区成人乙肝疫苗接种情况及影响因素分析[J]. 中国健康教育, 2020, 36( 3): 259- 261, 284. DOI: 10.16168/j.cnki.issn.1002-9982.2020.03.015.
[35]	YUAN QL, WANG FZ, ZHENG H, et al. Hepatitis B vaccination coverage among health care workers in China[J]. PLoS One, 2019, 14( 5): e0216598. DOI: 10.1371/journal.pone.0216598.
[36]	AN J, JIN N, XIE JR, et al. Vaccination coverage of hepatitis B and associated factors among health care workers in Gansu province[J]. Hum Vaccin Immunother, 2024, 20( 1): 2383509. DOI: 10.1080/21645515.2024.2383509.
[37]	HOU XB, LI N, ZHANG HL, et al. Hepatitis B virus infection and vaccination among people who use drugs in Xi’an, China[J]. Vaccine, 2024, 42( 24): 126259. DOI: 10.1016/j.vaccine.2024.126259.
[38]	WANG C, WANG YX, HUANG XJ, et al. Prevalence and factors associated with hepatitis B immunization and infection among men who have sex with men in Beijing, China[J]. PLoS One, 2012, 7( 10): e48219. DOI: 10.1371/journal.pone.0048219.
[39]	DOLHAIN J, JANSSENS W, DINDORE V, et al. Infant vaccine co-administration: Review of 18 years of experience with GSK’s hexavalent vaccine co-administered with routine childhood vaccines[J]. Expert Rev Vaccines, 2020, 19( 5): 419- 443. DOI: 10.1080/14760584.2020.1758560.
[40]	World Health Organization. Vaccination schedule for Hepatitis B[EB/OL].[ 2024-11-25]. https://immunizationdata.who.int/pages/schedule-by-disease/hepatitisb.html?ISO_3_CODE=&TARGETPOP_GENERAL=. https://immunizationdata.who.int/pages/schedule-by-disease/hepatitisb.html?ISO_3_CODE=&TARGETPOP_GENERAL=
[41]	BAYLISS J, NISSEN M, PRAKASH D, et al. Control of vaccine preventable diseases in Australian infants: Reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine[J]. Hum Vaccin Immunother, 2021, 17( 1): 176- 190. DOI: 10.1080/21645515.2020.1764826.
[42]	KLEIN NP, ABU-ELYAZEED R, CHEUVART B, et al. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: A randomized trial in the United States[J]. Hum Vaccin Immunother, 2019, 15( 4): 809- 821. DOI: 10.1080/21645515.2018.1549449.
[43]	SCHWARZ TF, BEHRE U, ADELT T, et al. Long-term antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy[J]. Hum Vaccin Immunother, 2019, 15( 1): 235- 241. DOI: 10.1080/21645515.2018.1509658.
[44]	LANG S, LOVING S, MCCARTHY ND, et al. Two centuries of immunisation in the UK(part II)[J]. Arch Dis Child, 2020, 105( 3): 216- 222. DOI: 10.1136/archdischild-2019-317707.
[45]	KALIES H, GROTE V, SIEDLER A, et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure[J]. Vaccine, 2008, 26( 20): 2545- 2552. DOI: 10.1016/j.vaccine.2008.03.001.
[46]	ZHENG H, WANG FZ, ZHANG GM, et al. An economic analysis of adult hepatitis B vaccination in China[J]. Vaccine, 2015, 33( 48): 6831- 6839. DOI: 10.1016/j.vaccine.2015.09.011.